



September 1, 2025

BSE Limited,
Floor 25, P. J. Towers Dalal
Street, Fort,
Mumbai - 400 001

National Stock Exchange of India Limited,
Exchange Plaza, Bandra-Kurla Complex,
Bandra (E),
Mumbai - 400051

Scrip Code: 530019

Symbol: JUBLPHARMA

Sub.: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), 2015 (Listing Regulations')

Dear Sir,

In continuation of our disclosure dated June 12, 2025, regarding the sale and transfer of the Active Pharmaceutical Ingredients (API) business of the Company ("Undertaking") on a slump sale basis to Jubilant Biosys Limited ("JBL"), a wholly owned subsidiary of the Company, we wish to inform you that:

- Dr. Ramakrishnan Arul (DIN: 08236356), Whole-Time Director of the Company, has resigned effective close of business hours on August 31, 2025.
- Dr. Tushar Gupta, Chief of Operations- Contract Research, Development, and Manufacturing Organization (CRDMO) Business of the Company, Senior Management Personnel of Jubilant Pharmova Limited has resigned effective close of business hours on August 31, 2025.

These resignations are pursuant to their transfer to company's subsidiary, Jubilant Biosys Limited, where they will assume responsibilities effective September 1, 2025.

The details required pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are given in enclosed Annexure - 1 and Annexure - 2.

The resignation letters received from Dr. Ramakrishnan Arul and Dr. Tushar Gupta are also attached as Annexure - 3 and 4 respectively.

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624



The above information will also be available on the website of the Company at www.jubilantpharmova.com.

We request you to take the same on record.

Thanking you,

Yours faithfully,

For Jubilant Pharmova Limited

Naresh Kapoor

Company Secretary

Encl.: As above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

Disclosure of information pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular dated November 11, 2024:

Annexure – 1

Name	Dr. Ramakrishnan Arul
Reason for change viz. appointment, re-appointment, — resignation, removal, death or otherwise;	Resigned pursuant to transfer of API Business of the Company to Company's subsidiary, Jubilant Biosys Limited, where he will assume responsibilities effective September 1, 2025
Date of appointment/re- appointment/cessation (as applicable) & term of appointment/- re-appointment;	August 31, 2025
Brief Profile (in case of appointment)	Not Applicable
Disclosure of relationship between directors (in case of appointment of a director)	Not Applicable

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

Annexure – 2

Name	Dr. Tushar Gupta
Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Resigned pursuant to transfer of API Business of the Company to Company's subsidiary, Jubilant Biosys Limited, where he will assume responsibilities effective September 1, 2025
Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment;	August 31, 2025
Brief Profile (in case of appointment)	Not Applicable
Disclosure of relationship between directors (in case of appointment of a director)	Not Applicable

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

August 31, 2025

To
The Board of Directors
Jubilant Pharmova Limited
1A, Sector-16A,
Noida - 201301,
Uttar Pradesh

Subject: Resignation as a Director and Whole-Time Director


Dear Sir,

Pursuant to the sale and transfer of the Active Pharmaceutical Ingredients (API) business of the Company ("Undertaking") on a slump sale basis to Jubilant Biosys Limited (JBL), a wholly-owned subsidiary company, I hereby render my resignation as a Director and Whole-Time Director of the Company w.e.f. close of business hours of August 31, 2025.

This decision is in alignment with my transition to Jubilant Biosys Limited, where I will assume new responsibilities effective September 1, 2025, as part of the strategic restructuring of the API business.

I would like to express my gratitude to the Board for the support and cooperation extended to me during my tenure as a Director and Whole-Time Director of the Company.

Yours Faithfully



Ramakrishnan Arul
DIN: 08236356

August 31, 2025

To
The Board of Directors
Jubilant Pharmova Limited
1A, Sector-16A,
Noida – 201301,
Uttar Pradesh

Subject: Resignation as a Chief of Operations- Contract Research, Development, and Manufacturing Organization (CRDMO) Business of Jubilant Pharmova Limited

Dear Sir,

Pursuant to the sale and transfer of the Active Pharmaceutical Ingredients (API) business of the Company ("Undertaking") on a slump sale basis to Jubilant Biosys Limited (JBL), a wholly-owned subsidiary company, I hereby render my resignation as a Chief of Operations- Contract Research, Development, and Manufacturing Organization (CRDMO) Business of Jubilant Pharmova Limited w.e.f. close of business hours of August 31, 2025.

This decision is in alignment with my transition to Jubilant Biosys Limited, where I will assume new responsibilities effective September 1, 2025, as part of the strategic restructuring of the API business.

Yours Faithfully



Tushar Gupta